Validation of radiotracer specificity for activated caspase-3 was demonstrated by the invariable uptake in caspase-3-deficient MCF-7 human breast cancer cells treated with the alkylating agent 4-hydroperoxycyclophosphamide (4-HC) compared to untreated cells. This evidence concerns the gene CASP3 and breast carcinoma.